2024
Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease
Armillei M, Lomakin I, Del Rosso J, Grada A, Bunick C. Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease. Antibiotics 2024, 13: 270. PMID: 38534705, PMCID: PMC10967556, DOI: 10.3390/antibiotics13030270.Peer-Reviewed Original ResearchSoft tissue infectionsTetracycline class antibioticsTreatment of dermatological diseasesMechanism of protein synthesis inhibitionClindamycin useStaphylococcal infectionsTissue infectionsClinical presentationAnti-inflammatory propertiesHidradenitis suppurativaEffective antibioticsTreatment optionsClindamycinClinical evidenceAcne vulgarisClinical basisProtein synthesis inhibitionDermatological indicationsAmeliorate inflammationAntibiotic resistanceDermatology practiceBacterial ribosomeDermatological diseasesClass antibioticsLesion formation
2022
Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology
Grada A, Ghannoum MA, Bunick CG. Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology. Antibiotics 2022, 11: 722. PMID: 35740129, PMCID: PMC9220064, DOI: 10.3390/antibiotics11060722.Peer-Reviewed Original ResearchBroad-spectrum tetracyclineInflammatory dermatosesAntibiotic stewardshipStaphylococcal infectionsClinical effectivenessSkin diseasesCutaneous staphylococcal infectionsReported adverse eventsFirst-line agentsInflammatory skin diseaseMucous membrane pemphigoidAnti-inflammatory propertiesStaphylococcal skin infectionsAntibiotic resistanceTetracycline-class antibioticsAdverse eventsAcne rosaceaClinical findingsCutaneous infectionsAcne vulgarisSkin infectionsMedicine careStrong rationaleInfectionMultiple skin diseases